Nucleus RadioPharma has announced plans to build two new facilities totaling over 100,000 square feet in Mesa, Arizona and Springhouse, Pennsylvania.
 
These facilities will house research, development, and commercial production capabilities under one roof, giving time and scale advantage to Nucleus’ partners. The expansion aims to provide the entire radiopharmaceutical industry with new capabilities from novel isotope utilization to broad patient access.
 
The new facilities address two critical challenges in the radiopharmaceutical market: a shortage of high-quality development and manufacturing capabilities, and the geographic limitations imposed by the short half-life of many radiopharmaceuticals. By enabling production closer to patients and clinical trial sites, Nucleus aims to improve treatment accessibility and accelerate drug development timelines.
 
“To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them,” said Nucleus RadioPharma CEO Charles S. Conroy. “Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%.”
 
The 53,000-square-foot Mesa, Ariz. site and the 48,000-square-foot facility in Spring House Innovation Park north of Philadelphia are strategically positioned to serve key markets. Prominent Nucleus backers, including Fox Chase Cancer Center and Mayo Clinic, will benefit from the increased scale and geographical proximity these facilities provide.
 
Furthermore, the expansion is expected to create approximately 50 new jobs in each location, contributing to local economic growth and strengthening these regions as hubs for healthcare innovation.